After a clinical trial for a new medication, relative risks for disability and mortality were observed. What can be concluded about the effects of the active drug compared to placebo?

• A. Significantly higher for disability, significantly lower for mortality
• B. No significant difference for both outcomes
• C. Significantly lower for disability, no significant difference for mortality
• D. Significantly lower for disability, significantly higher for mortality

Answer: (A)

The conclusion drawn from the trial that indicates a significantly higher relative risk for disability while simultaneously showing a significantly lower relative risk for mortality suggests a nuanced understanding of the drug's effects.

When a medication results in a significant increase in the risk for disability, it implies that patients taking the active drug may experience more unfavorable health outcomes or functional impairments compared to those receiving the placebo. This finding is critical as it highlights potential adverse effects of the drug on quality of life and functional status.

Conversely, the finding of a significantly lower risk for mortality indicates that the drug may confer some protective effect against death compared to placebo. This could be due to a variety of mechanisms, such as improved management of a condition or a reduced likelihood of death from certain causes, even though this comes at the expense of increasing disability.

Together, these two assertions highlight the importance of considering both survival and quality of life when evaluating treatment options. Thus, it provides a comprehensive view of the drug's risk-benefit profile, revealing that while it may increase the likelihood of disability, it also appears to enhance survival outcomes. This brings to light the complex interplay between treatment effects and patient outcomes, an essential aspect of clinical decision-making.